The Build/Buy/Partner Dilemma: Balancing Risk and Opportunity for Strategic MedTech Growth

MedTech and HealthTech companies operate in an environment marked by rapid and accelerating innovation. This makes fast, well-informed decision-making a strategic imperative, requiring companies to balance evolving clinical needs, shifting customer expectations, and dynamic competitive forces. In this context, the decision to build internal capabilities, acquire an emerging innovator, merge with an established competitor, license a new technology, or partner with other commercial organizations is pivotal, as it can profoundly shape a company’s competitive advantage and growth trajectory.

Each path offers inherent advantages and risks. Broadly speaking, building in-house capabilities offers a high degree of customization and control, avoids complexities related to data and intellectual property sharing, and preserves full ownership of the final product. However, this approach typically requires substantial upfront and ongoing investment, sustained access to specialized talent, and longer development timelines. By contrast, acquiring a company developing innovative technologies with strong market potential can significantly accelerate time to market. At the same time, acquisitions demand considerable initial capital and may introduce operational, technical, and cultural integration challenges that can slow execution and, in some cases, dilute value. To mitigate risk, portfolio investment decisions require a high level of confidence in strategic fit, execution readiness, and long-term value creation. Licensing represents an intermediate option between in-house development and acquisition, allowing access to innovation with lower capital requirements, but at the expense of control and with the potential for long-term dependency.

Partnerships can mitigate several of the challenges described above by sharing risk, cost, and expertise. They can also enable faster experimentation and validation, particularly in emerging application areas where specialized know-how would be difficult or time-consuming to acquire. However, partnerships may constrain strategic autonomy, complicate data governance, and raise intellectual property and exclusivity concerns. For these reasons, partnerships are generally best suited when entering adjacent markets or therapeutic areas, where leveraging established expertise, capabilities, or distribution channels is preferable to building them from scratch.

Choosing the Right Path

Navigating the build/buy/partner dilemma requires a clear understanding of a company’s strategic priorities, stage of development, long-term growth objectives, resources, and risk tolerance. For example, a full-scale acquisition may be appropriate for a large MedTech company with a global footprint and strong integration capabilities, whereas a phased approach may be better suited to smaller companies with more limited access to capital. Such an approach could begin with a partnership during early product development and progress to an equity investment or full acquisition as confidence in the solution’s value increases (e.g., through clinical validation or reimbursement alignment) or as market conditions become more favorable.

While the optimal path is inherently company and technology-specific, several key questions and core action items consistently underpin effective build/buy/partner decision-making.

1. Strategic Fit and Core Competencies
   How central is the technology, platform, or capability to long-term differentiation and competitive advantage? If the answer is “very central,” acquiring a focused innovator that can unlock differentiation, either immediately or through further internal development, may represent the most appropriate path
2. Unmet Need and Technology Maturity
   How significant is the clinical or operational unmet need being addressed? Is there an existing solution on the market, or in development, that meaningfully alleviates current pain points?
   As a rule of thumb, the magnitude and urgency of the unmet need should be proportional to the level of investment and risk the company is willing to assume. At the same time, more mature technologies tend to be better suited for acquisitions, minimizing the risk that lengthy internal development cycles result in reduced differentiation or products that are no longer aligned with market demand at launch
3. Market Dynamics and Competitive Landscape
   What is the current and near-term competitive environment? Are there well-funded incumbents, fast-growing startups, or technology trends that favor speed over control?
   Market pressure and competitive intensity often determine whether building, buying, or partnering is the most viable option. For instance, in increasingly competitive markets, the need for rapid action may make a partnership or a targeted acquisition an effective option for dislodging competitors
4. Time to Market and Value Capture
   How critical is speed to value creation and market share capture?
   When rapid market entry is essential to establish leadership, meet customer demand, or pre-empt competitors, acquisitions, licensing, or partnerships may offer meaningful advantages over internal development
5. Evidence and Technical Risk
   Is there sufficient clinical, technical, or real-world evidence to support the proposed use of the technology?
   Early-stage concepts with limited validation may warrant a partnership or staged investment, whereas more mature assets may justify acquisitions or internal scale-up
6. Value Proposition and Economic Impact
   Has the value of the technology been clearly defined and tested with end users, clinicians, patients, payers, and/or purchasing decision-makers? Is the value perceived as incremental or transformational?
   The amount of additional development required to reach an acceptable value proposition for market entry and adoption strongly influences decision-making, as it is closely linked to return-on-investment timelines. In general, the closer a technology is to a commercially viable product, the more compelling an acquisition becomes
7. Regulatory, Reimbursement, and Access Considerations
   How well does the chosen approach align with regulatory pathways, data requirements, and reimbursement environments across target geographies?
   Strategies that de-risk regulatory approval and accelerate clinical adoption should be prioritized, particularly for capital-intensive technologies. Building in-house typically carries the highest risk when significant evidence generation is required
8. Organizational Readiness and Execution Capability
   Does a company have the internal capabilities, operating model, and leadership bandwidth required to build, integrate, or effectively manage partnerships or acquisitions?
   Execution risk is often underestimated and can be a decisive factor in determining which path is most viable under current conditions. Smaller companies with limited access to capital tend to benefit most from strategic partnerships, which can mitigate financial and execution risk
9. Strategic Agility and Adaptability
   Can strategic agility and adaptability be maintained as evidence and market conditions evolve or as strategic priorities change?
   Internal development offers long-term ownership and differentiation, but it may make it difficult to pivot quickly without a phased or modular approach. Acquisitions represent long-term commitments and generally offer low strategic flexibility, and may even result in investment losses if strategic assumptions change. By contrast, partnerships provide greater flexibility, enabling companies to test technologies or markets while deferring full commitment and preserving multiple exit paths, including scaling the relationship, acquiring assets, or internalizing capabilities

Evaluating Strategic Options

The build, buy, or partner dilemma rarely has a straightforward solution. Nevertheless, a structured, action-oriented decision framework can cut through the noise by allowing companies to compare strategic options side by side and systematically evaluate trade-offs related to cost, speed, control, and risk, in both qualitative and quantitative terms. By bringing structure to the evaluation process, such a framework not only helps determine which option best aligns with a company’s strategic objectives at a given point in time – often via a phase-gate process – but also sheds light on ways to mitigate downside risk while preserving the ability to adapt or pivot as technological innovation and market conditions evolve.

While every framework must be tailored to a company’s specific context and priorities, the core advantages, limitations, and ideal use cases associated with building, buying, partnering, or implementing hybrid approaches are summarized in the table below.

Conclusions

Technologies are not only evolving rapidly but also enabling successive waves of adjacent innovation. This is pushing companies of all sizes to adopt more agile decision-making processes and accelerate time to market to stay competitive and drive growth. Amplifying this dynamic is artificial intelligence, whose breakneck evolution is unlocking a broad range of capabilities across the care continuum that must be quickly assessed and translated into products with demonstrated, sustainable value – all before commercialization windows narrow and potential competitive advantages dissipate.

Against this backdrop, determining the most strategically sound path to market requires weighing a mix of internal and external factors, including strategic intent, long-term differentiation potential, organizational and technology readiness, and the speed at which the market is evolving or is expected to evolve.

A comparative summary outlining the conditions under which internal development, acquisition, partnership, or hybrid approaches offer the greatest advantage is presented below.

Veranex Can Help You Make Informed Build/Buy/Partner Decisions that Maximize Strategic Value and Accelerate Growth

Veranex Commercial Strategy & Market Access helps MedTech and HealthTech companies identify and execute the most effective paths to growth through tailored build, buy, and partner strategies across therapeutic areas. We work with large strategic companies and emerging innovators to assess growth opportunities, invest in innovation, evaluate partnership and acquisition options, and build internal capabilities that drive differentiation and support both organic and inorganic growth. We also support investors and corporate venture teams in optimizing portfolio strategies and evaluating M&A opportunities. In addition, we partner with startups to develop or refine go-to-market strategies, achieve key value-inflection milestones, and position their businesses for successful exit.

Explore the full list of the Commercial Strategy & Market Access practice capabilities here.

Related Reading: Strategic Expansion into Market Adjacencies

About the author: 

Cinzia Metallo, PhD, is Director in the Commercial Strategy and Market Access practice, specializing in Strategy and Innovation. Dr. Metallo leverages her scientific and entrepreneurial background to help companies of all sizes develop go-to-market strategies and commercial roadmaps, evaluate emerging market opportunities, conduct unmet need assessments, identify potential partners and investment targets, perform due diligence, and build robust forecasting models. She specializes in designing growth strategies around whitespace opportunities and guiding businesses in expanding their market presence through both organic and inorganic approaches. Her experience spans medical devices, digital technologies, software, and diagnostics across therapeutic areas such as oncology, immunology, neurology, cardiovascular, gastroenterology, and dermatology. She holds a Ph.D. in Neuroscience and a M.Sc. in Physics.

Beyond the Service Line:

CSMA at Veranex informs early Research & Strategy work to clarify where products can win and what evidence will matter at key inflection points. As programs advance, commercial insights shape design and development, clinical endpoints, regulatory pathways, and integrated evidence planning so each milestone increases adoption potential and enterprise value.

For strategics, we help prioritize and evaluate emerging innovations at scale. And through Veranex’s Innovation CRO (iCRO), we meet clients exactly where they are, delivering targeted expertise when and where it’s needed most, adding velocity to your vision.